Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome

Clinical outcome and mutations of 96 core-binding factor acute myeloid leukemia (AML) patients 18–60 years old were examined. Complete remission (CR) after induction was 94.6%. There was no significant difference in CR, leukemia-free-survival (LFS) and overall survival (OS) between t(8;21) (N=67) an...

Descripción completa

Detalles Bibliográficos
Autores principales: Cher, C Y, Leung, G M K, Au, C H, Chan, T L, Ma, E S K, Sim, J P Y, Gill, H, Lie, A K W, Liang, R, Wong, K F, Siu, L L P, Tsui, C S P, So, C C, Wong, H W W, Yip, S F, Lee, H K K, Liu, H S Y, Lau, J S M, Luk, T H, Lau, C K, Lin, S Y, Kwong, Y L, Leung, A Y H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5030377/
https://www.ncbi.nlm.nih.gov/pubmed/27391574
http://dx.doi.org/10.1038/bcj.2016.51

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5030377/
https://www.ncbi.nlm.nih.gov/pubmed/27391574
http://dx.doi.org/10.1038/bcj.2016.51

Ejemplares similares